Tocagen Inc., a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells. The company's lead product candidate is Toca 511 & Toca FC that is under Phase III clinical trial for recurrent high-grade glioma. It is also developing Toca 511 & Toca FC in a Phase Ib clinical trial for metastatic cancers, including colorectal, pancreatic, breast, lung, and melanoma. In addition, the company is developing other RRVs to deliver genes to cancer cells against validated immunotherapy targets, such as the checkpoint protein PD-L1. Tocagen Inc. was founded in 2007 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TOCA
CUSIPN/A
Phone858-412-8400
Debt
Debt-to-Equity Ratio0.03
Current Ratio4.56
Quick Ratio4.56
Price-To-Earnings
Trailing P/E Ratio-3.05
Forward P/E Ratio-3.92
P/E GrowthN/A
Sales & Book Value
Annual Sales$40,000.00
Price / Sales4,044.86
Cash FlowN/A
Price / CashN/A
Book Value$3.59 per share
Price / Book2.26
Profitability
EPS (Most Recent Fiscal Year)($2.66)
Net Income$-38,920,000.00
Net Margins-130,944.75%
Return on Equity-70.79%
Return on Assets-54.69%
Miscellaneous
Employees67
Outstanding Shares19,950,000
Market Cap$180.76 million
Tocagen (NASDAQ:TOCA) Frequently Asked Questions
What is Tocagen's stock symbol?
Tocagen trades on the NASDAQ under the ticker symbol "TOCA."
How were Tocagen's earnings last quarter?
Tocagen Inc (NASDAQ:TOCA) announced its quarterly earnings data on Tuesday, August, 7th. The company reported ($0.81) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.56) by $0.25. The company earned $0.01 million during the quarter, compared to the consensus estimate of $2.01 million. Tocagen had a negative net margin of 130,944.75% and a negative return on equity of 70.79%. View Tocagen's Earnings History.
When is Tocagen's next earnings date?
What price target have analysts set for TOCA?
3 Wall Street analysts have issued twelve-month target prices for Tocagen's stock. Their forecasts range from $14.50 to $20.00. On average, they expect Tocagen's share price to reach $16.50 in the next year. This suggests a possible upside of 103.5% from the stock's current price. View Analyst Price Targets for Tocagen.
What is the consensus analysts' recommendation for Tocagen?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tocagen in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Tocagen.
Who are some of Tocagen's key competitors?
Some companies that are related to Tocagen include Aptinyx (APTX), CymaBay Therapeutics (CBAY), Crinetics Pharmaceuticals (CRNX), Kiniksa Pharmaceuticals (KNSA), Epizyme (EPZM), Geron (GERN), ANI Pharmaceuticals Inc Common Stock (ANIP), Vectura Group (VEGPF), Abeona Therapeutics (ABEO), Urogen Pharma (URGN), Viking Therapeutics (VKTX), Adamas Pharmaceuticals (ADMS), GlycoMimetics (GLYC), AC Immune (ACIU) and Progenics Pharmaceuticals (PGNX).
Who are Tocagen's key executives?
Tocagen's management team includes the folowing people:
- Mr. Martin J. Duvall, CEO & Director (Age 56)
- Mr. Thomas E. Darcy, Co-Founder & Director (Age 67)
- Mr. Mark G. Foletta CPA, Exec. VP & CFO (Age 57)
- Dr. Asha Das, Sr. VP & Chief Medical Officer (Age 53)
- Dr. Harry E. Gruber, Co-Founder, Pres of Science & Innovation and Director (Age 65)
When did Tocagen IPO?
(TOCA) raised $80 million in an initial public offering (IPO) on Thursday, April 13th 2017. The company issued 7,300,000 shares at a price of $10.00-$12.00 per share. Leerink Partners, Evercore ISI and Stifel acted as the underwriters for the IPO.
Has Tocagen been receiving favorable news coverage?
News headlines about TOCA stock have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern rates the sentiment of press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Tocagen earned a media and rumor sentiment score of 0.16 on Accern's scale. They also gave press coverage about the company an impact score of 46.55 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future. View Recent Headlines for Tocagen.
Who are Tocagen's major shareholders?
Tocagen's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.67%), FMR LLC (2.57%), Pure Financial Advisors Inc. (0.40%), Bank of New York Mellon Corp (0.24%), Granahan Investment Management Inc. MA (0.21%) and First Republic Investment Management Inc. (0.09%). Company insiders that own Tocagen stock include Asha Das, Harry E Gruber, Mark G Foletta and Paul Schimmel. View Institutional Ownership Trends for Tocagen.
Which institutional investors are selling Tocagen stock?
Which institutional investors are buying Tocagen stock?
TOCA stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., First Republic Investment Management Inc., Raymond James & Associates and Granahan Investment Management Inc. MA. Company insiders that have bought Tocagen stock in the last two years include Asha Das, Harry E Gruber, Mark G Foletta and Paul Schimmel. View Insider Buying and Selling for Tocagen.
How do I buy shares of Tocagen?
Shares of TOCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Tocagen's stock price today?
One share of TOCA stock can currently be purchased for approximately $8.11.
How big of a company is Tocagen?
Tocagen has a market capitalization of $180.76 million and generates $40,000.00 in revenue each year. The company earns $-38,920,000.00 in net income (profit) each year or ($2.66) on an earnings per share basis. Tocagen employs 67 workers across the globe.
How can I contact Tocagen?
Tocagen's mailing address is 3030 BUNKER HILL STREET SUITE 230, SAN DIEGO CA, 92109. The company can be reached via phone at 858-412-8400 or via email at [email protected]
MarketBeat Community Rating for Tocagen (NASDAQ TOCA)
MarketBeat's community ratings are surveys of what our community members think about Tocagen and other stocks. Vote "Outperform" if you believe TOCA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TOCA will underperform the S&P 500 over the long term. You may vote once every thirty days.
